The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial by Widschwendter, Peter et al.
Widschwendter et al. Breast Cancer Research  (2015) 17:129 
DOI 10.1186/s13058-015-0639-3RESEARCH ARTICLE Open AccessThe influence of obesity on survival in
early, high-risk breast cancer: results from
the randomized SUCCESS A trial
Peter Widschwendter1*†, Thomas WP Friedl1†, Lukas Schwentner1, Nikolaus DeGregorio1, Bernadette Jaeger1,
Amelie Schramm1, Inga Bekes1, Miriam Deniz1, Krisztian Lato1, Tobias Weissenbacher2, Bernd Kost2,
Ulrich Andergassen2, Julia Jueckstock2, Julia Neugebauer2, Elisabeth Trapp2, Peter A. Fasching3,
Matthias W. Beckmann3, Andreas Schneeweiss4, Ines Schrader5, Brigitte Rack2, Wolfgang Janni1
and Christoph Scholz1Abstract
Introduction: Obese breast cancer patients have worse prognosis than normal weight patients, but the level at
which obesity is prognostically unfavorable is unclear.
Methods: This retrospective analysis was performed using data from the SUCCESS A trial, in which 3754 patients
with high-risk early breast cancer were randomized to anthracycline- and taxane-based chemotherapy with or
without gemcitabine. Patients were classified as underweight/normal weight (body mass index (BMI) < 25.0),
overweight (BMI 25.0–29.9), slightly obese (BMI 30.0–34.9), moderately obese (BMI 35.0–39.9) and severely obese
(BMI ≥ 40.0), and the effect of BMI on disease-free survival (DFS) and overall survival (OS) was evaluated (median
follow-up 65 months). In addition, subgroup analyses were conducted to assess the effect of BMI in luminal A-like,
luminal B-like, HER2 (human epidermal growth factor 2)-positive and triple-negative tumors.
Results: Multivariate analyses revealed an independent prognostic effect of BMI on DFS (p = 0.001) and OS (p = 0.005).
Compared with underweight/normal weight patients, severely obese patients had worse DFS (hazard ratio (HR) 2.70,
95 % confidence interval (CI) 1.71–4.28, p < 0.001) and OS (HR 2.79, 95 % CI 1.63–4.77, p < 0.001), while moderately
obese, slightly obese and overweight patients did not differ from underweight/normal weight patients with regard to
DFS or OS. Subgroup analyses showed a similar significant effect of BMI on DFS and OS in patients with triple-negative
breast cancer (TNBC), but not in patients with other tumor subtypes.
Conclusions: Severe obesity (BMI≥ 40) significantly worsens prognosis in early breast cancer patients, particularly for
triple-negative tumors.
Trial registration: Clinicaltrials.gov NCT02181101. Registered September 2005.Introduction
Obesity is a major risk factor for morbidity throughout
the world [1]. It is associated with an increased risk of
mortality attributable to diabetes, kidney diseases, cor-
onary heart disease and other cardiovascular ailments
[2]. From 1980 to 2013, the prevalence of obesity and* Correspondence: p.widschwendter@gmx.de
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greater than 25.
Several studies have shown that BMI influences the
outcomes of breast cancer patients [3–6]; however, most
of these studies categorized all patients with BMI ≥ 30 as
obese. In a recent pooled analysis of four randomized
clinical trials (5683 patients), Pajares et al. defined differ-
ent levels of obesity (30–35 and > 35), and found that
patients with BMI > 35 had a significantly higher risk for
recurrence than did patients with BMI < 25, but patientsis article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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group (BMI < 25) [7]. This indicates that more research is
needed to evaluate the exact association between obesity
and breast cancer outcomes, in particular with respect to
the level of obesity at which there is an increased risk of
breast cancer recurrence. We therefore conducted a retro-
spective analysis of the effect of BMI on outcomes in
breast cancer patients treated with anthracycline- and
taxane-based chemotherapy within the prospective ran-
domized SUCCESS A trial. In addition, we performed
subgroup analyses to evaluate whether the effect of BMI
varied by tumor subtype.
Methods
Study design and patients
In the open-label, phase III clinical trial SUCCESS A
(EudraCT 2005-000490-21), patients with high-risk breast
cancer (histopathological proof of axillary lymph node
metastases (pN1–3) or high-risk node-negative breast
cancer defined as tumor size ≥ pT2, histological grade 3,
negative hormone receptor status or age ≤ 35 years) were
randomized to adjuvant chemotherapy treatment with
three cycles of epirubicin, fluorouracil and cyclophospha-
mide (FEC, 500/100/500 mg/m2, every 3 weeks) followed
by either three cycles of docetaxel (Doc, 100 mg/m2,
every 3 weeks) or three cycles of docetaxel and gemci-
tabine (DocG, docetaxel 75 mg/m2 every 3 weeks plus
gemcitabine 1000 mg/m2 day 1 and 8 every 3 weeks).
After the end of chemotherapy, patients with hormone
receptor-positive disease received tamoxifen for 2 years.
Premenopausal patients continued tamoxifen treatment
for an additional 3 years, while postmenopausal pa-
tients switched to anastrozole treatment for 3 years. In-
clusion and exclusion criteria as well as therapeutic
details are published elsewhere [8]. Body weight and
height were measured before the start of chemotherapy,
and BMI was calculated as weight in kilograms divided
by the square of height in meters [9]. Patients were
classified as underweight (BMI < 18.5 kg/m2; n = 45),
normal weight (BMI 18.5–24.9 kg/m2; n = 1713),
overweight (BMI 25.0–29.9 kg/m2; n = 1208), slightly
obese (BMI 30.0–34.9 kg/m2; n = 554), moderately
obese (BMI 35.0–39.9 kg/m2; n = 177) or severely obese
(BMI ≥ 40.0 kg/m2; n = 57). For all analyses, under-
weight and normal weight patients were combined into
one group (underweight/normal weight, n = 1758)
because of the low number of patients with a BMI
below 18.5 kg/m2. Treatment, therapy and monitoring
were in accordance with the statutory provisions deter-
mined by the involved ethics committees of the Ludwig
Maximilians University Munich, the German Federal
Institute for Drugs and Medical Devices (BfArM) and
good clinical practice (GCP). The trial was approved by
the ethics committee of the medical faculty of theLudwig Maximilians University (project number: 076–05;
EudraCT 2005-000490-21). All patients gave written in-
formed consent for participating in the SUCCESS A trial.
In total, 3754 patients at 271 study centers were ran-
domized for the SUCCESS A trial between September
2005 and March 2007. Patient and tumor characteristics
of the patients are shown in Table 1.
For subgroup analysis according to molecular tumor
subtypes, patients were categorized into four groups:
luminal A like (hormone receptor positive, human
epidermal growth factor receptor 2 (HER2) negative,
G1/G2), luminal B like (hormone receptor positive,
HER2 negative, G3), HER2 positive (all HER2-positive
tumors) and triple negative (hormone receptor negative,
HER2 negative) [10, 11]. Due to missing values for
hormone receptor and/or HER2 status, molecular sub-
types could be determined for only 3670 of the 3754
randomized patients (Table 1).
Data analysis
Descriptive statistics for the categorical data are pro-
vided in terms of absolute and relative frequencies. The
non-normally distributed continuous variable age is de-
scribed by medians and ranges. Associations between
BMI group and patient or tumor characteristics were
evaluated using the Kruskal-Wallis H test for age, the
Mantel-Haenszel linear-by-linear association chi-square
test for trends for the ordered categorical variables
tumor size, nodal stage and grading, and the chi-square
test for all other categorical variables.
Patient outcomes were analyzed in terms of both
disease-free survival (DFS; with local, contralateral and
distant disease recurrence as well as secondary primary
tumors and death from any cause defined as the event)
and overall survival (OS; with death from any cause de-
fined as the event). Time-to-event data (median follow-
up 65 months, range 1–96 months) were analyzed using
the Kaplan-Meier method and summarized using me-
dians, and 95 % confidence intervals, and survival curves
for different BMI groups were compared using log-rank
tests. All time-to-event intervals were measured from
time of the primary diagnosis to date of the event or
date of the last adequate follow-up in case no event was
reported. To evaluate whether BMI constitutes an inde-
pendent prognostic factor, we used Cox proportional
hazards regression models adjusted for age (continuous),
tumor size (pT1, pT2, pT3, pT4), nodal stage (pN0,
pN1, pN2, pN3), tumor grade (G1, G2, G3), histological
type (ductal, lobular, other), hormone receptor status
(positive, negative), HER2 status (positive, negative),
menopausal status (premenopausal, postmenopausal),
type of surgery (breast conserving, mastectomy), chemo-
therapy treatment (FEC-Doc, FEC-DocG), antihormone
therapy (yes, no) and undertreatment (fewer than
Table 1 Distribution of patient and tumor characteristics by body mass index (BMI) group
Total
(n = 3754)
BMI (kg/m2) p valuea
<25.0 25.0–29.9 30.0–34.9 35.0–39.9 ≥40.0
Underweight/normal
weight
Overweight Slightly
obese
Moderately
obese
Severely
obese
(n = 1758) (n = 1208) (n = 554) (n = 177) (n = 57)
Age (years) Median 53.0 50.0 56.0 58.0 58.0 54.0 <0.001b
Range 21–86 21–86 22–79 32–77 33–74 29–74
Menopausal status Premenopausal 1565 (41.7 %) 932 (53.0 %) 410 (33.9 %) 153 (27.6 %) 52 (29.4 %) 18 (31.6 %) <0.001c
Postmenopausal 2189 (58.3 %) 826 (47.0 %) 798 (66.1 %) 401 (72.4 %) 125 (70.6 %) 39 (68.4 %)
Tumor size pT1 1552 (41.3 %) 866 (49.3 %) 455 (37.7 %) 161 (29.1 %) 56 (31.6 %) 14 (24.6 %) <0.001d
pT2 1929 (51.4 %) 785 (44.7 %) 666 (55.1 %) 342 (61.7 %) 101 (57.1 %) 35 (61.4 %)
pT3 198 (5.3 %) 73 (4.2 %) 70 (5.8 %) 35 (6.3 %) 14 (7.9 %) 6 (10.5 %)
pT4 52 (1.4 %) 18 (1.0 %) 13 (1.1 %) 13 (2.3 %) 6 (3.4 %) 2 (3.5 %)
Unknown 23 (0.6 %) 16 (0.9 %) 4 (0.3 %) 3 (0.5 %) 0 (0.0 %) 0 (0.0 %)
Nodal stage pN0 1273 (33.9 %) 660 (37.5 %) 370 (30.6 %) 153 (27.6 %) 67 (37.9 %) 23 (40.4 %) <0.001d
pN1 1705 (45.4 %) 789 (44.9 %) 564 (46.7 %) 265 (47.8 %) 68 (38.4 %) 19 (33.3 %)
pN2 511 (13.6 %) 212 (12.1 %) 174 (14.4 %) 94 (17.0 %) 24 (13.6 %) 7 (12.3 %)
pN3 236 (6.3 %) 76 (4.3 %) 94 (7.8 %) 40 (7.2 %) 18 (10.2 %) 8 (14.0 %)
Unknown 29 (0.8 %) 21 (1.2 %) 6 (0.5 %) 2 (0.4 %) 0 (0.0 %) 0 (0.0 %)
Histological grading G1 176 (4.7 %) 81 (4.6 %) 59 (4.9 %) 27 (4.9 %) 8 (4.5 %) 1 (1.8 %) 0.126d
G2 1783 (47.5 %) 848 (48.2 %) 576 (47.7 %) 255 (46.0 %) 82 (46.3 %) 22 (38.6 %)
G3 1773 (47.2 %) 814 (46.3 %) 568 (47.0 %) 270 (48.7 %) 87 (49.2 %) 34 (59.6 %)
Unknown 22 (0.6 %) 15 (0.9 %) 5 (0.4 %) 2 (0.4 %) 0 (0.0 %) 0 (0.0 %)
Histological type Invasive ductal 3060 (81.5 %) 1434 (81.6 %) 992 (82.1 %) 435 (78.5 %) 148 (83.6 %) 51 (89.5 %) 0.337c
Invasive lobular 419 (11.2 %) 188 (10.7 %) 138 (11.4 %) 72 (13.0 %) 19 (10.7 %) 2 (3.5 %)
Other 253 (6.7 %) 121 (6.9 %) 73 (6.0 %) 45 (8.1 %) 10 (5.6 %) 4 (7.0 %)
Unknown 22 (0.6 %) 15 (0.9 %) 5 (0.4 %) 2 (0.4 %) 0 (0.0 %) 0 (0.0 %)
Hormone receptor
status
Negative 1100 (29.3 %) 531 (30.2 %) 337 (27.9 %) 163 (29.4 %) 44 (24.9 %) 25 (43.9 %) 0.049c
Positive 2633 (70.1 %) 1212 (68.9 %) 866 (71.7 %) 390 (70.4 %) 133 (75.1 %) 32 (56.1 %)
Unknown 21 (0.6 %) 15 (0.9 %) 5 (0.4 %) 1 (0.2 %) 0 (0.0 %) 0 (0.0 %)
HER2 status Negative 2787 (74.2 %) 1304 (74.2 %) 887 (73.4 %) 417 (75.3 %) 135 (76.3 %) 44 (77.2 %) 0.838c
Positive 883 (23.5 %) 418 (23.8 %) 292 (24.2 %) 122 (22.0 %) 39 (22.0 %) 12 (21.1 %)
Unknown 84 (2.2 %) 36 (2.0 %) 29 (2.4 %) 15 (2.7 %) 3 (1.7 %) 1 (1.8 %)
Molecular subtype Luminal A like 1426 (38.0 %) 673 (38.3 %) 454 (37.6 %) 222 (40.1 %) 63 (35.6 %) 14 (24.6 %) 0.050c
Luminal B like 619 (16.5 %) 262 (14.9 %) 214 (17.7 %) 93 (16.8 %) 39 (22.0 %) 11 (19.3 %)
HER2 positive 883 (23.5 %) 418 (23.8 %) 292 (24.2 %) 122 (22.0 %) 39 (22.0 %) 12 (21.1 %)
Triple negative 742 (19.8 %) 369 (21.0 %) 219 (18.1 %) 102 (18.4 %) 33 (18.6 %) 19 (33.3 %)
Unknown 84 (2.2 %) 36 (2.0 %) 29 (2.4 %) 15 (2.7 %) 3 (1.7 %) 1 (1.8 %)
Type of surgery Breast conserving 2638 (70.3 %) 1205 (68.5 %) 859 (71.1 %) 399 (72.0 %) 135 (76.3 %) 40 (70.2 %) 0.229c
Mastectomy 1097 (29.2 %) 539 (30.7 %) 345 (28.6 %) 154 (27.8 %) 42 (23.7 %) 17 (29.8 %)
Unknown 19 (0.5 %) 14 (0.8 %) 4 (0.3 %) 1 (0.2 %) 0 (0.0 %) 0 (0.0 %)
Chemotherapy FEC-DocG 1856 (49.4 %) 865 (49.2 %) 614 (50.8 %) 261 (47.1 %) 85 (48.0 %) 31 (54.4 %) 0.580c
FEC-Doc 1898 (50.6 %) 893 (50.8 %) 594 (49.2 %) 293 (52.9 %) 92 (52.0 %) 26 (45.6 %)
Undertreatment Yes (<6 cycles CT) 359 (9.6 %) 149 (8.5 %) 113 (9.4 %) 64 (11.6 %) 24 (13.6 %) 9 (15.8 %) 0.029c
No (6 cycles CT) 3395 (90.4 %) 1609 (91.5 %) 1095 (90.6 %) 490 (88.4 %) 153 (86.4 %) 48 (84.2 %)
Widschwendter et al. Breast Cancer Research  (2015) 17:129 Page 3 of 11
Table 1 Distribution of patient and tumor characteristics by body mass index (BMI) group (Continued)
Antihormone therapy No 1048 (27.9 %) 500 (28.4 %) 331 (27.4 %) 149 (26.9 %) 43 (24.3 %) 25 (43.9 %) 0.061c
Yes 2677 (71.3 %) 1242 (70.6 %) 868 (71.9 %) 401 (72.4 %) 134 (75.7 %) 32 (56.1 %)
Unknown 29 (0.8 %) 16 (0.9 %) 9 (0.7 %) 4 (0.7 %) 0 (0.0 %) 0 (0.0 %)
HER2 human epidermal growth factor receptor 2, FEC-DocG 5-fluorouracile, epirubicine, cyclophosphamide – docetaxel, gemcitabine, FEC-Doc 5-fluorouracile,
epirubicine, cyclophosphamide – docetaxel, CT chemotherapy
aAll tests without category “unknown”
bKruskal-Wallis test
cChi-square test
dMantel-Haenszel linear-by-linear association chi-square test
Fig. 1 Kaplan–Meier plot of overall survival according to body mass
index (BMI) group (underweight/normal: BMI < 25.0 kg/m2; overweight:
BMI 25.0–29.9 kg/m2; slightly obese: BMI 30.0–34.9 kg/m2; moderately
obese: BMI 35.0–39.9 kg/m2; severely obese: BMI≥ 40.0 kg/m2)
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BMI group underweight/normal weight was used as
the reference group for the calculations of hazard ra-
tios (HR) and 95 % confidence intervals (CI).
Statistical analyses were performed using IBM® SPSS®
Statistics, version 21 (IBM Corp., Armonk, NY, USA).
All statistical tests were two-sided, and p values of less
than 0.05 were considered significant (no adjustment of
significance levels for multiple testing).
Results
Associations of BMI with patient and tumor
characteristics
Underweight/normal weight patients were younger on
average (median age 50 years) and more often premeno-
pausal (53 %) compared with overweight or obese patients
(median age 54 years or older; fewer than 34 % premeno-
pausal), and high BMI was associated with larger tumors
and increased nodal involvement (Table 1). Patients with
high BMI were also more likely to receive fewer than 6 cy-
cles of chemotherapy, i.e., to be undertreated. In addition,
severely obese patients (BMI ≥ 40.0 kg/m2) more often
had hormone receptor-negative tumors, fewer tumors of
the luminal A subtype and more tumors of the triple-
negative subtype compared to patients with BMI less than
40.0 kg/m2 (see Table 1).
Effect of BMI on disease-free and overall survival
Overall, 302 (8.0 %) patients died during the follow-up
period: 120 (6.8 %) in the underweight/normal weight
group, 99 (8.2 %) in the overweight group, 52 (9.4 %) in
the slightly obese group, 15 (8.5 %) in the moderately
obese group, and 16 (28.1 %) in the severely obese
group. Univariate survival analyses revealed significant
differences in OS among the BMI groups (log-rank test,
p < 0.001; see Fig. 1). Pairwise comparisons using log-
rank tests showed that OS differed significantly between
severely obese patients and all other BMI groups (all
p < 0.001), whereas there were no significant differ-
ences in OS among underweight/normal weight,
overweight, slightly obese and moderately obese pa-
tients (all p > 0.05). Fully adjusted multivariate Cox re-
gression analyses confirmed that BMI is a significantindependent prognostic factor for OS (p = 0.005;
Table 2). Overweight, slightly obese and moderately
obese patients had no significantly different OS rates
compared to underweight/normal weight patients
(Table 2). However, severely obese patients showed
significantly worse OS compared with underweight/
normal weight patients (HR 2.79, 95 % CI 1.63–4.77,
p < 0.001).
In total, a recurrence during the follow-up period was
observed in 502 (13.4 %) patients: 203 (11.5 %) in the
underweight/normal weight group, 177 (14.7 %) in the
overweight group, 80 (14.4 %) in the slightly obese group,
21 (11.9 %) in the moderately obese group, and 21
(36.8 %) in the severely obese group. Similar to the results
for OS, univariate analyses showed significant differences
in DFS among BMI groups (log-rank test, p < 0.001; Fig. 2),
and pairwise comparisons revealed significant differences
in DFS between severely obese patients and all other BMI
groups (log-rank tests, all p < 0.001). Multivariate analyses
confirmed the independent prognostic value of BMI for
DFS (p = 0.001; Table 2), but again, only severely obese
patients had significantly worse DFS compared with
underweight/normal weight patients (HR 2.70, 95 % CI
1.71–4.28, p < 0.001).
Table 2 Effect of body mass index (BMI) group (reference group underweight/normal weight) on overall survival (OS) and
disease-free survival (DFS) in fully adjusted multivariate Cox regressions
Outcome parameter Variable Hazard ratio 95 % CI p value
OS BMI group 0.005
Overweight vs. underweight/normal weight 1.00 0.75–1.32 0.979
Slightly obese vs. underweight/normal weight 1.06 0.75–1.49 0.758
Moderately obese vs. underweight/normal weight 1.07 0.62–1.86 0.799
Severely obese vs. underweight/normal weight 2.79 1.63–4.77 <0.001
DFS BMI group 0.001
Overweight vs. underweight/normal weight 1.18 0.95–1.45 0.129
Slightly obese vs. underweight/normal weight 1.06 0.81–1.40 0.664
Moderately obese vs. underweight/normal weight 0.96 0.61–1.51 0.849
Severely obese vs. underweight/normal weight 2.70 1.71–4.28 <0.001
CI confidence interval
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according to molecular tumor subtypes
The results of the univariate survival analyses and
survival plots for the different BMI groups according
to the four molecular tumor subtypes are presented
in Fig. 3 for OS and Fig. 4 for DFS. The effects of
BMI group on OS and DFS as calculated based on
fully adjusted multivariate Cox regressions are pre-
sented in Table 3.
The lack of a significant effect of BMI group on
survival in luminal A-like breast cancer as revealed
by univariate log-rank tests was confirmed by fully
adjusted multivariate Cox regressions, showing that
BMI group had no significant independent prognostic
value for OS or DFS (OS: p = 0.530; DFS: p = 0.851).
Univariate log-rank tests showed significant differences
among BMI groups with respect to DFS for patientsFig. 2 Kaplan–Meier plot of disease-free survival according to body
mass index (BMI) group (underweight/normal: BMI < 25.0 kg/m2;
overweight: BMI 25.0–29.9 kg/m2; slightly obese: BMI 30.0–34.9 kg/m2;
moderately obese: BMI 35.0–39.9 kg/m2; severely obese: BMI≥ 40.0 kg/m2)with luminal B-like breast cancers, and with respect
to both OS and DFS for patients with HER2-positive
breast cancers. However, fully adjusted multivariate
Cox regressions showed no independent effect of BMI
group on OS or DFS in patients with luminal B-like
or HER2-positive breast cancers (see Table 3). Con-
sistent significant effects of BMI group on outcomes
in both univariate and multivariate analyses were
found only for patients with triple-negative breast
cancer (TNBC). Univariate analyses showed that OS
and DFS differed significantly among BMI groups and
multivariate analyses confirmed the independent prog-
nostic effect of BMI group on OS (p = 0.015) and
DFS (p = 0.011). However, similar to the results for
the full data set, the effect of BMI in TNBC was only
apparent for severely obese patients, who had signifi-
cantly worse OS and DFS compared to underweight/
normal weight patients, while no significant hazard
ratios were observed for overweight, slightly obese or
moderately obese patients compared with under-
weight/normal weight patients (see Table 3).
Discussion
This retrospective analysis of data collected in the ran-
domized controlled SUCCESS A trial shows significantly
worse outcomes (OS, DFS) in severely obese patients
(BMI ≥ 40 kg/m2), but not in moderately obese (BMI
35.0–39.9 kg/m2), slightly obese (BMI 30.0–34.9 kg/m2),
or overweight (BMI 25.0–29.9 kg/m2) patients compared
with underweight/normal weight BMI < 25.0 kg/m2) pa-
tients with early breast cancer.
The overall negative effect of obesity on outcomes in
breast cancer patients is well known and has recently
been confirmed by two large meta-analyses [3, 12].
However, heterogeneous patient samples, different stat-
istical approaches and the fact that the obesity and
Fig. 3 Kaplan–Meier plots of overall survival according to body mass index (BMI) group (underweight/normal, overweight, slightly obese,
moderately obese, severely obese) in patients with tumor subtypes luminal A like (a), luminal B like (b), human epidermal growth factor receptor
2 (HER2) positive (c), and triple negative (d)
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included studies hamper a more detailed analysis of the
association between obesity and outcome with regard
to the extent of the negative effect associated with dif-
ferent obesity levels. Large single clinical trials are bet-
ter suited to evaluate the effect of BMI on outcomes for
defined breast cancer patient cohorts and treatment
regimens. Retrospective analyses of 2887 node-positive
breast cancer patients enrolled in the randomized phase
III trial BIG 02–98 and of 1310 node-positive high-risk
breast cancer patients enrolled in the randomized phase
III ADEBAR trial showed worse DFS and OS rates for
obese (BMI ≥ 30) compared with nonobese (BMI < 30)
women [5, 13]. However, to our knowledge, our study
is the first analysis of a large homogenous patient sam-
ple from a prospective randomized clinical phase III
trial with modern adjuvant chemotherapy (anthracycline-
and taxane-based) that investigated the impact of different
stages of obesity on breast cancer outcomes. Our results
demonstrate that analyses that are based solely on
comparing obese (BMI ≥ 30) with nonobese (BMI < 30)patients might not be sufficient to evaluate the effect of
obesity on breast cancer outcome, as we found a signifi-
cant effect only for severe obesity, but not for moderate or
slight obesity.
In our study, analysis of the different subgroups of
breast cancer revealed no significant impact of obesity
on outcomes in the luminal A-like, luminal B-like and
HER2-positive subtypes, but significantly poorer DFS
and OS in severely obese compared with underweight/
normal weight patients with triple-negative breast
cancer.
The recently published secondary analysis of the
Women’s Health Initiative (WHI) randomized clinical
trials demonstrated that for women older than 50 years
obesity grade 2 or 3 (i.e., BMI > 35.0) was strongly asso-
ciated with the risk for hormone receptor-positive breast
cancer [14]. Thus, it seems surprising that we did not
find a significant effect of obesity on survival in patients
with breast cancer of the hormone receptor-positive lu-
minal A and luminal B subtype. However, generally the
data regarding the effect of BMI on survival in different
Fig. 4 Kaplan–Meier plots of disease-free survival according to body mass index (BMI) group (underweight/normal, overweight, slightly obese,
moderately obese, severely obese) in patients with tumor subtypes luminal A like (a), luminal B like (b), human epidermal growth factor receptor
2 (HER2) positive (c), and triple negative (d)
Widschwendter et al. Breast Cancer Research  (2015) 17:129 Page 7 of 11breast cancer subtypes are quite heterogeneous and in-
consistent. A meta-analysis of 21 studies comprising
more than 80,000 patients yielded no evidence that the
association of obesity with breast cancer outcomes dif-
fers by hormone receptor status [15]. Similarly, Pajares
and coauthors, who found significantly poorer outcomes
for patients with BMI ≥ 35 compared to patients with
BMI < 25, stated that the magnitude of the effect was
similar across different subtypes (estrogen receptor (ER)/
progesterone (PR) positive and HER2 negative; HER2
positive; triple negative) [7]. In contrast, an analysis of
pooled data from three adjuvant trials of the Eastern
Cooperative Oncology Group with anthracycline-based
chemotherapies in 6885 patients revealed significantly
poorer outcomes for obese patients (BMI ≥ 30) than for
nonobese patients with hormone receptor-positive dis-
ease, but no negative impact of obesity on survival in pa-
tients with other breast cancer subtypes [6]. A recent
pooled analysis evaluated the impact of BMI on DFS and
OS according to breast cancer subtypes in 8872 patients
with primary breast cancer treated with neoadjuvantchemotherapy [16]. The authors found that overall
obese (BMI 30 to < 40) and very obese (BMI ≥ 40) pa-
tients had shorter DFS and OS than normal weight
(BMI 18.5 to < 25) patients, and subgroup analyses re-
vealed consistent negative effects of BMI on survival in
luminal-like (ER/PR-positive and HER2-negative) and
TNBC but not in HER2-positive tumors. In our study,
the DFS and OS hazard ratios for severe obesity (refer-
ence group underweight/normal weight) were similar
for the luminal B-like, HER2-positive and triple-
negative subtypes (range 2.78–3.85), indicating that the
lack of significance in the luminal B-like and HER2-
positive subgroups found in our study might be attrib-
utable to the smaller number of severely obese patients
and the resulting reduced statistical power. In contrast,
DFS and OS hazard ratios for severe obesity were much
lower in the luminal A-like subgroup (1.51 and 0.82, re-
spectively), suggesting that even severe obesity does not
constitute an additional risk factor for patients with
low-risk breast cancer of the luminal A-like subtype.
We are not aware of any other study that evaluated the
Table 3 Effect of body mass index (BMI) group (reference group underweight/normal weight) on overall survival (OS) and
disease-free survival (DFS) according to molecular subtype in fully adjusted multivariate Cox regressions
Molecular subtype Outcome parameter Hazard ratio 95 % CI p value
Luminal A like OS BMI group 0.530
Overweight vs. underweight/normal weight 0.86 0.48–1.52 0.594
Slightly obese vs. underweight/normal weight 1.32 0.71–2.47 0.384
Moderately obese vs. underweight/normal weight 1.72 0.69–4.30 0.247
Severely obese vs. underweight/normal weight 1.51 0.20–11.42 0.688
DFS BMI group 0.851
Overweight vs. underweight/normal weight 1.21 0.81–1.82 0.359
Slightly obese vs. underweight/normal weight 1.10 0.66–1.83 0.714
Moderately obese vs. underweight/normal weight 1.42 0.65–3.09 0.382
Severely obese vs. underweight/normal weight 0.82 0.11–6.06 0.849
Luminal B like OS BMI group 0.384
Overweight vs. underweight/normal weight 0.87 0.44–1.75 0.701
Slightly obese vs. underweight/normal weight 1.29 0.55–3.00 0.561
Moderately obese vs. underweight/normal weight 0.58 0.17–2.07 0.405
Severely obese vs. underweight/normal weight 2.84 0.71–11.40 0.141
DFS BMI group 0.156
Overweight vs. underweight/normal weight 1.18 0.72–1.93 0.513
Slightly obese vs. underweight/normal weight 1.46 0.78–2.74 0.235
Moderately obese vs. underweight/normal weight 0.76 0.29–2.00 0.584
Severely obese vs. underweight/normal weight 3.32 1.17–9.46 0.024
HER2 positive OS BMI group 0.425
Overweight vs. underweight/normal weight 0.86 0.46–1.62 0.646
Slightly obese vs. underweight/normal weight 0.82 0.37–1.80 0.612
Moderately obese vs. underweight/normal weight 1.36 0.43–4.35 0.601
Severely obese vs. underweight/normal weight 2.78 0.75–10.34 0.128
DFS BMI group 0.198
Overweight vs. underweight/normal weight 1.08 0.68–1.69 0.754
Slightly obese vs. underweight/normal weight 0.81 0.44–1.50 0.503
Moderately obese vs. underweight/normal weight 1.09 0.43–2.79 0.858
Severely obese vs. underweight/normal weight 3.28 1.14–9.48 0.028
Triple negative OS BMI group 0.015
Overweight vs. underweight/normal weight 1.41 0.88–2.25 0.155
Slightly obese vs. underweight/normal weight 1.27 0.67–2.41 0.458
Moderately obese vs. underweight/normal weight 0.51 0.12–2.21 0.368
Severely obese vs. underweight/normal weight 3.85 1.69–8.77 0.001
DFS BMI group 0.011
Overweight vs. underweight/normal weight 1.34 0.91–1.97 0.140
Slightly obese vs. underweight/normal weight 1.29 0.77–2.17 0.335
Moderately obese vs. underweight/normal weight 0.36 0.09–1.48 0.154
Severely obese vs. underweight/normal weight 3.02 1.50–6.08 0.002
CI confidence interval, HER2 human epidermal growth factor receptor 2
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and distinguished between luminal A and luminal B
tumors. It might be speculated that an increased risk in
severely obese patients with hormone receptor-positive
tumors could have been masked by anti-hormonal
therapy in our study, in particular in the group of
patients with low-risk luminal A-type breast cancer.
The fact that the analysis of data gained in the Eastern
Cooperative Oncology Group adjuvant trial E1199
showed a strong negative effect of obesity on outcome
in patients with hormone receptor-positive breast
cancer that received a similar endocrine treatment as
the patients in our study (i.e., either tamoxifen alone or
tamoxifen followed by an aromatase inhibitor) [6] does
not argue against such a possible masking effect of anti-
hormone therapy, as the median follow-up time in the
E1199 trial was 95 months and thus far exceeded the
duration of anti-hormone therapy. Taken together, the
conflicting data on the effect of obesity on survival in
different subtypes of breast cancer indicate that the
mechanistic link between obesity and breast cancer sur-
vival is complex and not yet fully understood.
Obesity is known to be often accompanied by cardio-
vascular risk factors such as glucose and lipid disorders
and hypertension, and the adverse effect of high BMI on
long-term outcome is likely mediated at least partly
through these obesity-related metabolic abnormalities. A
recent meta-analysis showed that even normal-weight
individuals were at an increased risk for all-cause mor-
tality and cardiovascular events if they were metabolic-
ally unhealthy, while – on the other hand – obese
individuals had an increased risk even if they were meta-
bolically healthy when only studies with a follow-up of
at least 10 years were analyzed [17]. Another large re-
cent meta-analysis found that the presence of metabolic
abnormalities (i.e., metabolic syndrome) is associated
with an increased breast cancer risk in adult women
[18]. These results point to a link between metabolic
syndrome, obesity and breast cancer and suggest that
the presence of metabolic abnormalities should be in-
cluded in future studies evaluating the effect of obesity
on survival in breast cancer patients.
A strength of this study is the fact that the analysis
is based on a homogenous patient sample from a large
prospective randomized clinical trial, which reduces
the potentially confounding effects of heterogeneous
patient samples and different treatment regimens. In
addition, this is the first study in which the effects of
BMI on survival in breast cancer patients were evalu-
ated separately for the four biological tumor subtypes
using three distinct classes of obesity. Limitations of
the study are the lack of information on Ki-67, needed
for more accurate subdivision of different breast can-
cer subtypes, and the low number of patients withsevere obesity (leading to limited statistical power in
particular regarding the subgroup analyses with respect
to the four tumor subtypes). In addition, no data on
metabolic abnormalities (metabolic syndrome) were
available. Furthermore, it is unknown whether the re-
duced survival observed in severely obese breast can-
cer patients is a direct consequence of obesity itself
(as, for example, the increased chemotherapy doses
might partly diffuse into fat tissue and thus not fully
reach the tumor) or rather caused by obesity-related
comorbidities.
Conclusions
In conclusion, this single-study analysis of 3754 pa-
tients demonstrated that only severe obesity (BMI ≥ 40)
is associated with worse outcomes in operable high-risk
early breast cancer, especially in the triple-negative sub-
type. More studies are needed to evaluate the effect of
obesity on outcomes in breast cancer patients with re-
spect to both the obesity level that constitutes an inde-
pendent risk factor for reduced survival, and the effect
of obesity in different tumor subtypes.
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